Comparison of in vitro susceptibilities to levofloxacin and ciprofloxacin with Pseudomonas aeruginosa and Stenotrophomonas maltophilia isolated from cystic fibrosis patients in Northern Ireland

British Journal of Biomedical Science

Volumn 62, Issue 1, 2005, Pages 30-32

  McKnight, A J ^a   Shaw, A ^a   Goldsmith, C E ^a   Clarke, L ^a   Millar, B C ^a   McCaughan, J ^b   Elborn, J S ^a   Reid, A ^c   Moore, John E ^a  

^a BELFAST CITY HOSPITAL   (United Kingdom)

^b ROYAL GROUP OF HOSPITALS   (United Kingdom)

^c ROYAL BELFAST HOSPITAL FOR SICK CHILDREN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AZTREONAM; CHAPERONIN; CIPROFLOXACIN; LEVOFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIMENTIN;

ADULT; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM ISOLATE; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HUMAN; IN VITRO STUDY; INTERMETHOD COMPARISON; IRELAND; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFECTION; SPUTUM CULTURE; STENOTROPHOMONAS MALTOPHILIA;

BACTERIA (MICROORGANISMS); PSEUDOMONAS; PSEUDOMONAS AERUGINOSA; STENOTROPHOMONAS MALTOPHILIA;

EID: 16444379103     PISSN: 09674845     EISSN: None     Source Type: Journal    
DOI: 10.1080/09674845.2005.11978067     Document Type: Article

References (13)

1. Conway SP, Brownlee KG, Denton M, Peckham DG. Antibiotic treatment of multidrug-resistant organisms in cystic fibrosis. Am J Respir Med 2003; 2: 321-2.
2. San Gabriel P, Zhou J, Tabibi S, Chen Y, Trauzzi M, Saiman L. Antimicrobial susceptibility and synergy studies of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 2004; 48: 168-71.
3. Rosenfeld M, Ramsey BW, Gibson RL. Pseudomonas acquisition in young patients with cystic fibrosis: pathophysiology, diagnosis, and management. Curr Opin Pulm Med 2003; 9: 492-7.
4. Denton M, Kerr KG. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin Microbiol Rev 1998; 11: 57-80.
5. Clarke L, Moore JE, Millar BC et al. Development of a diagnostic PCR assay that targets a heat-shock protein gene (groES) for detection of Pseudomonas spp. in cystic fibrosis patients. J Med Microbiol 2003; 52: 759-63.
6. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 3rd edn. Approved standard M100-S7. Wayne PA, 1997.
7. Jones RN, Erwin M, Croco JL. Critical appraisal of E test for the detection of fluoroquinolone resistance. J Antimicrobiol Chemother 1996; 38: 21-5.
8. Gesu GP, Marchetti F, Piccoli L, Cavallero A. Levofloxacin and ciprofloxacin in vitro activities against 4,003 clinical bacterial isolates collected in 24 Italian laboratories. Antimicrobiol Agents Chemother 2003; 47: 816-9.
9. Swings J, de Vos P, van den Mooter M, Deley J. Transfer of Pseudomonas maltophilia Hugh 1981 to the genus Xanthomonas as Xanthomonas maltophilia (Hugh 1981) comb. nov. Int J System Bacteriol 1983; 33: 409-13.
10. Palleroni NJ, Bradbury JE Stenotrophomonas, a new bacterial genus for Xanthomonas maltophilia (Hugh 1980) Swings et al. 1983. Int J System Bacteriol 1993; 43: 606-9.
11. Ribera A, Domenech-Sanchez A, Ruiz J, Benedi VJ, Jimenez de Anta MT, Vila J. Mutations in gyrA and parC QRDRs are not relevant for quinolone resistance in epidemiological unrelated Stenotrophomonas maltophilia clinical isolates. Microbial Drug Resistance 2002; 8: 245-51.
12. Akasaka T, Tanaka M, Yamaguchi A, Sato K. Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance. Antimicrobial Agents Chemother 2001; 45: 2263-8.
13. Gillespie SH, Voelker LL, Ambler JE, Traini C, Dickens A. Fluoroquinolone resistance in Streptococcus pneumonias: evidence that gyrA mutations arise at a lower rate and that mutation in gyrA or parC predisposes to further mutation. Microbial Drug Resistance 2003; 9: 17-24.